mirikizumab (LY3074828) - Eli Lilly
Mirikizumab: Primary completion of P3 VIVID-1 trial (NCT03926130) for Crohn's disease in Feb 2022 (Eli Lilly) - Apr 23, 2020 - Q1 2020 Results: Completion of P3 VIVID-1 trial for Crohn's disease in Jul 2023; Primary completion and completion of P3 VIVID-2 trial (NCT04232553) for Crohn's disease Nov 2023 
Trial completion date • Trial primary completion date Crohn's disease • Immunology • Inflammation • Inflammatory Bowel Disease
https://investor.lilly.com/static-files/68230d7a-ba20-43dc-979b-fea529a5e6c4
 
Apr 23, 2020
 
 
7b3f0e42-9970-4140-8888-615c0972ac78.jpg